+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Liquid Biopsy Markets By Cancer Type, By Usage Type & Potential Market Size Analysis - With Executive and Consultant Guides, Including Customized Forecasting and Analysis 2020-2024

  • ID: 4850541
  • Report
  • March 2020
  • Region: Global
  • 409 Pages
  • Howe Sound Research
1 of 4
Liquid Biopsy Moving from Development to Growth Phase. Huge Cancer Screening Opportunity Looms.

FEATURED COMPANIES

  • Abbott Diagnostics
  • Bioarray Genetics
  • Circulogene
  • Freenome
  • Integrated Diagnostics
  • Perkin Elmer
  • MORE

The Screening, Diagnostic, Therapy Selection, Recurrence Monitoring and Screening Market Potential are all explored in this report.

What is the size of the huge screening opportunity? This huge opportunity is explored by country with an astounding result for the Global Potential Market Size!

A revolution in cancer diagnostics is occurring using in vitro blood testing to identify cancer DNA. The technology has created the possibility of widespread screening for all types of cancers with a blood test.

GRAIL, a new company with impressive backing, has announced a single blood test to detect all cancers. The company is now working on a 10,000-plus subject study, called the Circulating Cell-Free Genome Atlas (CCGA) to help identify cancer early. The technology is moving faster than the market. New technology that definitively identifies disease conditions from blood samples is poised to replace expensive invasive surgical biopsy procedures. The market is still in its infancy but has just moved out of the development phase and into the growth phase. The impact on the health care industry is enormous. The report forecasts the market size out to 2024. In addition, the report looks at potential market sizes by country, by cancer and by the four types of usage: screening, diagnosis, therapy selection and recurrence monitoring.

Use independent research that makes you the expert. Get our research team working for you by ordering this comprehensive report. Your credit card order sends the report to your inbox instantly. Check all your licensing options but don't worry, your order is available as a credit if you wish to upgrade to more information. Get an extra player on your team as unlimited assistance and breakout data is included with your purchase.

Circulating Tumor Cells? Cell Free DNA? Exosomes? Find out about the technology in readily understood terms that explain the jargon. Find the opportunities and pitfalls. Understand growth expectations and the ultimate potential market size.

The report includes detailed breakouts for 15 Countries and 4 Regions along with breakouts for Lung, Breast, Colorectal, Prostate, Cervical, Precancer, Melanoma and Other Cancers as well as breakouts by Screening/Early Detection, Diagnostic, Therapy Monitoring and Recurrence Monitoring.

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Abbott Diagnostics
  • Bioarray Genetics
  • Circulogene
  • Freenome
  • Integrated Diagnostics
  • Perkin Elmer
  • MORE

1. Introduction and Market Definition
1.1 What is Liquid Biopsy?
1.2 The Sequencing Revolution
1.3 Market Definition
1.3.1 Revenue Market Size
1.4 Methodology
1.4.1 Authors
1.4.2 Sources
1.5 A Spending Perspective on Liquid Biopsy
1.5.1 An Historical Look at Clinical Testing

2. Market Overview
2.1 Players in a Dynamic Market
2.1.1 Academic Research Lab
2.1.2 Diagnostic Test Developer
2.1.3 Genomic Instrumentation Supplier
2.1.3.1 Cell Separation and Viewing Instrumentation Supplier
2.1.4 Pharmaceutical/Reagent Supplier
2.1.5 Independent Testing Lab
2.1.6 Public National/regional lab
2.1.7 Hospital lab
2.1.8 Physician Lab
2.1.9 Audit Body
2.1.10 Certification Body
2.2 Using Biopsies
2.2.1 Cancer
2.2.2 Precancerous conditions
2.2.3 Inflammatory conditions
2.3 Biopsy Sites
2.4 The Situation Today – Biopsy Analysis
2.5 Evidence of Cancer - Liquid Biopsy Technology
2.5.1 The Big Picture on Liquid Biopsy Technology
2.5.2 The Role of CTCs
2.5.2.1 Types of CTCs
2.5.2.2 CellSearch Detection- Ultimate Sensitivity
2.5.2.3 Epic Sciences Detection- Imaging Takes the Lead
2.5.2.4 Maintrac Detection – The Microscope
2.5.2.5 Other Methods
2.5.3 ctDNA – Going Mainstream?
2.5.4 Exosomes and Micro Vesicles – New Kid on the Block
2.5.5 The Multiple Play
2.6 Cancer Treatment Protocol Under Siege
2.6.1 Issues to Liquid Biopsy Adoption – Double Diagnostics
2.6.2 The Cancer Screening Market Opportunity
2.6.2.1 GRAIL – What Is It?
2.6.3 Cancer Management vs. Diagnosis
2.6.3.1 The Role of Risk Assessment
2.6.3.2 Managing Therapy
2.6.3.3 Monitoring Disease – What Is It?
2.6.4 Phases of Adoption – Looking into The Future
2.6.5 The Promise of Liquid Biopsy
2.7 Structure of Industry Plays a Part
2.7.1 Hospital Testing Share
2.7.2 Economies of Scale
2.7.2.1 Hospital vs. Central Lab
2.7.3 Physician Office Lab’s
2.7.4 Physician’s and POCT
2.8 Profiles of Key Players
Abbott Diagnostics
AccuraGen Inc
Acuamark Diagnostics
Admera Health, LLC
Agena Bioscience, Inc
Agilent
Amoy Diagnostics Co., Ltd.
Anchor Dx
ANGLE plc
ApoCell, Inc
ArcherDx, Inc.
Asuragen
AVIVA Biosciences
Baylor Miraca Genetics Laboratories
Beckman Coulter, Inc.
Becton, Dickinson and Company
BGI Genomics Co. Ltd
Bioarray Genetics
Biocartis
Biocept, Inc
Biodesix Inc.
BioFluidica
bioMérieux Diagnostics
Bioneer Corporation
Bio-Rad Laboratories, Inc
Bio-Techne
Bioview
Bolidics
Boreal Genomics
Caris Molecular Diagnostics
CellMax Life
Cepheid (now Danaher)
Chronix Biomedical
Circulogene
Clinical Genomics
Cynvenio
Cytolumina Technologies Corp.
CytoTrack
Datar Cancer Genetics Limited
Diagenode Diagnostics
Diagnologix LLC
Enzo Life Sciences, Inc.
Epic Sciences
Epigenomics AG
Eurofins Scientific
Exosome Diagnostics
Exosome Sciences
Fluidigm Corp
Fluxion Biosciences
Foundation Medicine
Freenome
GeneFirst Ltd
Genetron Health (Beijing) Co., Ltd
Genomic Health
GILUPI Nanomedizin
Grail, Inc
Guardant Health
HansaBiomed
HeiScreen
Helomics
Horizon Discovery
iCellate
Illumina
Incell Dx
Inivata
Integrated Diagnostics
Janssen Diagnostics
MDNA Life SCIENCES, Inc
MDx Health
Menarini Silicon Biosystems
Millipore Sigma
Miltenyi Biotec
miR Scientific
Molecular MD
Myriad Genetics/Myriad RBM
NantHealth, Inc.
Natera
NeoGenomics
New Oncology
Novogene Bioinformatics Technology Co., Ltd
Oncocyte
OncoDNA
Oxford Nanopore Technologies
Perkin Elmer
Personal Genome Diagnostics
PrecisionMed
Promega
Qiagen Gmbh
Quidel
Rarecells SAS
RareCyte
Resolution Biosciences, Inc
Roche Molecular Diagnostics
Screencell
Siemens Healthineers
simfo GmbH
Singlera Genomics Inc
SRI International
Sysmex Inostics
Tempus Labs, Inc.
Thermo Fisher Scientific Inc
Thrive Earlier Detection
Trovagene
Volition

3. Market Trends
3.1 Factors Driving Growth
3.1.1 Non Invasive Game Changer
3.1.2 Lower Cost
3.1.3 Greater Accuracy
3.1.4 Wide Range of Potential Uses
3.1.5 Aging Population
3.2 Factors Limiting Growth
3.2.1 Lower prices
3.2.2 Lack of Standards
3.2.3 Protocol Resistance
3.2.4 Initial Adoption Has No Cost Savings
3.3 Instrumentation and Automation
3.3.1 Instruments Key to Market Share
3.3.2 Bioinformatics Plays a Role.
3.4 Diagnostic Technology Development
3.4.1 Next Generation Sequencing Fuels a Revolution
3.4.2 Impact of NGS on pricing
3.4.3 Pharmacogenomics Blurs Diagnosis and Treatment
3.4.4 CGES Testing, A Brave New World
3.4.5 Biochips/Giant magneto resistance based assay

4. Liquid Biopsy Recent Developments
4.1 Recent Developments – Importance and How to Use This Section
4.1.1 Importance of These Developments
4.1.2 How to Use This Section
Aethlon Medical Lands Grant for Exosome Isolation Device
Biolidics to Develop Liquid Biopsy Breast Cancer Test
Liquid Biopsy Equal to Tissue to Indicate Immunotherapy Response
Exact Sciences buys Genomic Health
Multi-Gene Liquid Biopsy Breast Cancer Panel
Bio-Techne receives FDA breakthrough device for prostate cancer liquid biopsy
Thrive to Develop Earlier Detection of Multiple Cancer Types
Guardant Health Liquid Biopsy Test to be Covered by EviCore
Liquid biopsy combines Illumina’s ‘ultradeep’ sequencing with Grail’s machine learning.
Biocept Partnership Offering for Liquid Biopsy Adds Several Key Services
Natera Commercializes Tumor Whole Exome Sequencing from Plasma
Sienna Buys Liquid Biopsy & Exosome Isolation Technology
Inivata Completes £39.8M Series B Funding Round
Bio-Rad Clinical ddPCR Test, Diagnostic System Get FDA Clearance
CellMax, Medigen Biotech Partner in Colorectal Cancer Clinical Trials
Biodesix Acquires Integrated Diagnostics
Predicine, Kintor Pharmaceuticals Partner on Clinical Trials, CDx
Bio-Techne to Acquire Exosome Dx for Up to $575M
GRAIL Announces Data on Detection of Early-Stage Lung Cancers
CellMax Life, IncellDx Partner to Develop Circulating Tumor Cell Tests
Personal Genome Diagnostics Nets $75M in Series B Financing
Circulogene Licenses Liquid Biopsy Tech to Turkish Lab
Liquid Biopsy Firms Move Toward Multianalyte Detection
In a first, China approves Amoy’s lung cancer liquid biopsy
Liquid Biopsy Shows Promise for Colon Cancer
Bio-Rad Continues to Advance Digital PCR Tech, Liquid Biopsy Tests Into Commercial
Clinical Market
Liquid Biopsy Combo Improved Sensitivity for EGFR Mutations in NSCLC
Startups race to develop cancer screens from DNA
Bristol-Myers, NEA drive cancer test player to $75M round
Avalon GloboCare, Da An Gene Collaborate on Liquid Biopsy Diagnostics
OncoDNA Inks Russian Distribution Deal With Genext
Biocept Prices $15M Public Offering
UgenTec, MDxHealth Partner To Develop AI Software for Prostate Cancer Tests
Exact Sciences Shares Drop on Threat From Liquid Biopsy
Precision for Medicine Acquires ApoCell
NeoGenomics to Acquire Genoptix for Cash, Stocks
PGDx Liquid Biopsy Assay to be Used in Cancer Drug Study
Liquid Biopsy IDs More NSCLC Mutations in Study of Guardant Test
Inivata Gets Draft Medicare Coverage Determination for Lung Cancer Test

5. The Global Market for Liquid Biopsy
5.1 Liquid Biopsy – Global Market Overview by Country
5.1.1 Table – Global Market by Country
5.1.2 Chart - Global Market by Country

6. Global Liquid Biopsy Markets – By Type of Cancer
6.1 Global Market by Cancer Type - Overview
6.1.1 Table – Global Market by Cancer Type
6.1.2 Chart – Global Market by Cancer Type – 2019/2024 Comparison
6.1.3 Chart – Global Market by Cancer Type – 2019
6.1.4 Chart – Global Market by Cancer Type –2024
6.1.4 Chart – Global Market by Cancer Type – Share by Year
6.2 Liquid Biopsy Breast Cancer
6.2.1 Table Breast Cancer Testing – by Country
6.2.2 Chart - Breast Cancer Testing Growth
6.3 Liquid Biopsy Colorectal Cancer
6.3.1 Table Colorectal Cancer Testing – by Country
6.3.2 Chart - Colorectal Cancer Testing Growth
6.4 Liquid Biopsy Cervical Cancer
6.4.1 Table Cervical Cancer Testing – by Country
6.4.2 Chart - Cervical Cancer Testing Growth
6.5 Liquid Biopsy Lung Cancer
6.5.1 Table Lung Cancer Testing – by Country
6.5.2 Chart - Lung Cancer Testing Growth
6.6 Liquid Biopsy Precancer
6.2.1 Table Precancer Testing – by Country
6.6.2 Chart - Precancer Testing Growth
6.7 Liquid Biopsy Prostate Cancer
6.7.1 Table Prostate Cancer Testing – by Country
6.7.2 Chart - Prostate Cancer Testing Growth
6.8 Liquid Biopsy Melanoma
6.8.1 Table Melanoma Testing – by Country
6.8.2 Chart - Melanoma Testing Growth
6.9 Liquid Biopsy Blood Cancer
6.9.1 Table Blood Cancer Testing – by Country
6.9.2 Chart - Blood Cancer Testing Growth
6.10 Liquid Biopsy Other Cancer
6.10.1 Table Other Cancer Testing – by Country
6.10.2 Chart - Other Cancer Testing Growth

7. Global Liquid Biopsy Markets – By Type of Usage
7.1 Global Market by Usage Type - Overview
7.1.1 Table – Global Market by Usage Type
7.1.2 Chart – Global Market by Usage Type – 2019/2024 Comparison
7.1.3 Chart – Global Market by Usage Type – 2019
7.1.4 Chart – Global Market by Usage Type –2024
7.1.4 Chart – Global Market by Usage Type – Share by Year
7.2 Liquid Biopsy Screening & Early Detection
7.2.1 Table Screening Testing – by Country
7.2.2 Chart - Screening Testing Growth
7.3 Liquid Biopsy Diagnosis
7.3.1 Table Diagnosis Testing – by Country
7.3.2 Chart - Diagnosis Testing Growth
7.4 Liquid Biopsy Therapy Selection
7.4.1 Table Therapy Selection – by Country
7.4.2 Chart - Therapy Selection Growth
7.5 Liquid Biopsy Monitoring
7.5.1 Table Monitoring – by Country
7.5.2 Chart - Monitoring Growth

8. Potential Market Opportunity Sizes
8.1 Potential Cancer Screening by Country: Lung, Breast & Colorectal
8.2 Potential Cancer Screening by Country: Prostate, Other Cancer & All Cancer
8.3 Potential Market Size - Cancer Diagnosis
8.4 Potential Market Size – Therapy Selection

Appendices
I. United States Medicare System: January 2019 Clinical Laboratory Fees Schedule
II. FDA Approved Human Genetic Tests
III. Pharmacogenomic Biomarkers in Drug Labeling

Table of Tables
Table 1 Medicare Clinical Lab Expenditures Actual & Forecast 2004 to 2020 ($Billion)
Table 2 Market Players by Type
Table 3 Biopsy Sites
Table 4 Advantages of Liquid Biopsy in Screening Market
Table 5 Five Factors Driving Growth
Table 6 Four Factors Limiting Growth
Table 7 Key Diagnostic Laboratory Technology Trends
Table 8 Next Generation Sequencing Technologies – Speed and Cost
Table 9 - Global Liquid Biopsy Market by Region
Table 10 Global Market by Cancer Type
Table 11 Liquid Biopsy Breast Cancer by Country
Table 12 Liquid Biopsy Colorectal Cancer by Country
Table 13 Cervical Cancer Testing by Country
Table 14 Lung Cancer Testing by Country
Table 15 Precancer Testing by Country
Table 16 Prostate Cancer Testing by Country
Table 17 Liquid Biopsy Melanoma by Country
Table 18 Liquid Biopsy Blood Cancer by Country
Table 19 Liquid Biopsy Other Cancer Testing by Country
Table 20 Global Market by Usage Type
Table 21 Liquid Biopsy Screening by Country
Table 22 Liquid Biopsy Diagnosis by Country
Table 23 Therapy Selection Testing by Country
Table 24 Monitoring Testing by Country
Table 25 Potential Screening Market: Lung, Breast & Colorectal
Table 26 Potential Screening Market: Prostate, Other & All
Table 27 Potential Cancer Diagnosis Market Size
Table 28 Potential Cancer Management Market Size
Table 29 2019 Laboratory Fee Schedule
Table 30 FDA Approved Human Genetic tests
Table 31 Pharmacogenomic Biomarkers

Table of Figures
Figure 1 Medicare Clinical Lab Expenditures 2004 to 2020 ($Million)
Figure 2 Comparison of Liquid Biopsy Classes
Figure 3 Characteristics of Different Vesicle Types
Figure 4 Percentage of World Population Over 65
Figure 5 2019 Global Market Density Chart
Figure 6 MDx Market by Cancer - 2019 vs. 2024
Figure 7 Liquid Biopsy Market 2019
Figure 8 Liquid Biopsy Market 2024
Figure 9 Liquid Biopsy Share by Year
Figure 10 Breast Cancer Testing Growth
Figure 11 Colorectal Cancer Testing Growth
Figure 12 Cervical Cancer Testing Growth
Figure 13 Lung Cancer Testing Growth
Figure 14 Precancer Testing Growth
Figure 15 Prostate Cancer Testing Growth
Figure 16 Melanoma Testing Growth
Figure 17 Blood Cancer Testing Growth
Figure 18 Other Cancer Testing Growth
Figure 19 Liquid Biopsy Market by Usage Type - 2019 vs. 2024
Figure 20 Usage Market 2019
Figure 21 Usage Market 2024
Figure 22 Liquid Biopsy Usage Share by Year
Figure 23 Screening Testing Growth
Figure 24 Diagnosis Testing Growth
Figure 25 Therapy Selection Testing Growth
Figure 26 Monitoring Testing Growth

Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • ANGLE plc
  • AVIVA Biosciences
  • Abbott Diagnostics
  • AccuraGen Inc
  • Acuamark Diagnostics
  • Admera Health, LLC
  • Aethlon Medical
  • Agena Bioscience, Inc
  • Agilent
  • Amoy
  • Amoy Diagnostics Co., Ltd.
  • Anchor Dx
  • ApoCell, Inc
  • ArcherDx, Inc.
  • Asuragen
  • Avalon GloboCare
  • BGI Genomics Co. Ltd
  • Baylor Miraca Genetics Laboratories
  • Beckman Coulter, Inc.
  • Becton, Dickinson and Company
  • Bio-Rad Clinical
  • Bio-Rad Laboratories, Inc
  • Bio-Techne
  • BioFluidica
  • Bioarray Genetics
  • Biocartis
  • Biocept, Inc
  • Biodesix Inc.
  • Biolidics
  • Bioneer Corporation
  • Bioview
  • Boreal Genomics
  • Bristol-Myers
  • Caris Molecular Diagnostics
  • CellMax Life
  • Cepheid (now Danaher)
  • Chronix Biomedical
  • Circulogene
  • Clinical Genomics
  • Cynvenio
  • CytoTrack
  • Cytolumina Technologies Corp.
  • Da An Gene C
  • Datar Cancer Genetics Limited
  • Diagenode Diagnostics
  • Diagnologix LLC
  • Enzo Life Sciences, Inc.
  • Epic Sciences
  • Epigenomics AG
  • Eurofins Scientific
  • EviCore
  • Exact Sciences  
  • Exosome Diagnostics
  • Fluidigm Corp
  • Fluxion Biosciences
  • Foundation Medicine
  • Freenome
  • GILUPI Nanomedizin
  • GRAIL
  • GeneFirst Ltd
  • Genetron Health (Beijing) Co., Ltd
  • Genext
  • Genomic Health
  • Genoptix
  • Grail, Inc
  • Guardant Health
  • HansaBiomed
  • HeiScreen
  • Helomics
  • Horizon Discovery
  • Illumina
  • IncellDx
  • Inivata
  • Integrated Diagnostics
  • Janssen Diagnostics
  • Kintor Pharmaceuticals
  • MDNA Life SCIENCES, Inc
  • MDxHealth
  • Medigen Biotech
  • Menarini Silicon Biosystems
  • Millipore Sigma
  • Miltenyi Biotec
  • Molecular MD
  • Myriad Genetics/Myriad RBM
  • NEA
  • NantHealth, Inc.
  • Natera
  • NeoGenomics
  • New Oncology
  • Novogene Bioinformatics Technology Co., Ltd
  • OncoDNA
  • Oncocyte
  • Oxford Nanopore Technologies
  • Perkin Elmer
  • Personal Genome Diagnostics
  • Precision for Medicine
  • PrecisionMed
  • Predicine
  • Promega
  • Qiagen Gmbh
  • Quidel
  • RareCyte
  • Rarecells SAS
  • Resolution Biosciences, Inc
  • Roche Molecular Diagnostics
  • SRI International
  • Screencell
  • Siemens Healthineers
  • Sienna
  • Singlera Genomics Inc
  • Sysmex Inostics
  • Tempus Labs, Inc.
  • Thermo Fisher Scientific Inc
  • Thrive
  • Trovagene
  • UgenTec
  • Volition
  • bioMérieux Diagnostics
  • iCellate
  • miR Scientific
  • simfo GmbH
Note: Product cover images may vary from those shown
Adroll
adroll